Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

NCT: NCT06910306 · RECRUITING

NCT IDNCT06910306
StatusRECRUITING
Start Date2025-10-01
Completion2026-12-01

Brief Summary

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma

Frequently Asked Questions

What is Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma?

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma is a clinical trial registered under NCT06910306. Current status: RECRUITING.

What is the status of NCT06910306?

The current status of NCT06910306 (Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma) is: RECRUITING.

When did Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma start?

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma started on 2025-10-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑